home / stock / atai / atai quote
Last: | $1.30 |
---|---|
Change Percent: | 0.0% |
Open: | $1.35 |
Close: | $1.30 |
High: | $1.4 |
Low: | $1.29 |
Volume: | 539,118 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.3 | $1.35 | $1.3 | $1.4 | $1.29 | 539,118 | 07-02-2024 |
$1.35 | $1.34 | $1.35 | $1.3584 | $1.3 | 486,190 | 07-01-2024 |
$1.33 | $1.4 | $1.33 | $1.4 | $1.3 | 1,033,840 | 06-28-2024 |
$1.32 | $1.32 | $1.32 | $1.34 | $1.27 | 570,224 | 06-27-2024 |
$1.3 | $1.35 | $1.3 | $1.36 | $1.28 | 719,024 | 06-26-2024 |
$1.35 | $1.4 | $1.35 | $1.42 | $1.33 | 745,676 | 06-25-2024 |
$1.4 | $1.36 | $1.4 | $1.53 | $1.36 | 1,803,700 | 06-24-2024 |
$1.34 | $1.37 | $1.34 | $1.44 | $1.3 | 1,248,818 | 06-21-2024 |
$1.33 | $1.3 | $1.33 | $1.37 | $1.25 | 1,518,297 | 06-20-2024 |
$1.27 | $1.33 | $1.27 | $1.35 | $1.26 | 1,099,307 | 06-19-2024 |
$1.27 | $1.33 | $1.27 | $1.35 | $1.26 | 1,099,307 | 06-18-2024 |
$1.34 | $1.35 | $1.34 | $1.3787 | $1.32 | 599,683 | 06-17-2024 |
$1.37 | $1.35 | $1.37 | $1.38 | $1.33 | 489,594 | 06-14-2024 |
$1.34 | $1.33 | $1.34 | $1.38 | $1.33 | 678,352 | 06-13-2024 |
$1.32 | $1.37 | $1.32 | $1.4 | $1.31 | 1,012,181 | 06-12-2024 |
$1.32 | $1.37 | $1.32 | $1.39 | $1.31 | 772,302 | 06-11-2024 |
$1.4 | $1.4 | $1.4 | $1.435 | $1.3605 | 670,531 | 06-10-2024 |
$1.39 | $1.47 | $1.39 | $1.485 | $1.36 | 924,320 | 06-07-2024 |
$1.48 | $1.42 | $1.48 | $1.49 | $1.4 | 578,794 | 06-06-2024 |
$1.41 | $1.31 | $1.41 | $1.5 | $1.3 | 2,870,217 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s manage...
--News Direct-- Atai Life Sciences co-founder and co-CEO Florian Brand discussed initial results from Beckley Psytech’s phase 1 trial of its patent-protected psilocin ELE-101 in patients with major depressive disorder. Brand explained that ELE-101 is an intravenous (IV) formula...
About a week ago, an advisory committee to the U.S. Food and Drug Administration (FDA) rejected evidence supporting the approval of MDMA as an alternative treatment for post-traumatic stress disorder (PTSD). This is a deflating moment for many in psychedelic research who have, for years, conduc...